Coretag launches smart solutions for better healthcare


Coretag launches smart solutions for better healthcare

Coretag, a new dynamic biotech company, launches a radioligand platform technology for a range of therapeutic and diagnostic purposes. A radioligand is a radioactive biochemical that is used for diagnostic procedures or for studying the body’s receptor systems. Injected into the relevant tissue or administered into the bloodstream, the radioligand binds to its receptor on tumor celles surfaces. Coretag is determined to rapidly improve care with this platform technology.

Coretag’s radioligand therapeutics

Two radioligands therapeutics are currently being developed, both for the treatment of solid tumor cancer-types. Based on brachy-therapy and hyperthermia, they will have major impact as adjuvant to many existing forms of cancer therapies that are not 100% effective yet.

In the Therm-Core application, a radioligand is labeled with a magnetic atom and selectively heated by a MRI-scan induced magnetic field. This will highly precisely kill surrounding active tumor tissue.

The Actino-Core application is a form of radiotherapy from within the tumor, with which surrounding living cancer cells will be destroyed.

Coretag’s radioligand diagnostics

Coretag aims to launch an application named NC-Scan for use in patients in 2021. Based on selectively binding to necrotic cells, the NC-Scan will be the world’s first clinical application to determine chemotherapy efficacy within the first week of therapy. Clinical trials with patients with specific solid tumors will start early 2020 at world-renowned leading cancer institutes in Europe.

Chemotherapy for solid tumor is ineffective in 65% of cases. Currently, effectiveness can only be proved after up to 4-6 months, during which patients may be confronted with serious side-effects. If with the use of the NC-Scan efficacy is found lacking, an alternative regimen can be started without losing precious time. The NC-scan will thus have a major impact on quality of life, costs and survival.

Coretag’s origin

​Coretag has its origins in recognized cancer centers in the Netherlands, such as the Leiden University Medical Center and Erasmus Medical Center, Rotterdam. In 2019, Coretag set up its headquarters in Basel, Switzerland with branch offices in Rotterdam, the Netherlands, for upcoming clinical research